Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.

Verbrugge, Sue Ellen; Al, Marjon; Assaraf, Yehuda G; Niewerth, Denise; van Meerloo, Johan; Cloos, Jacqueline; van der Veer, Michael; Scheffer, George L; Peters, Godefridus J; Chan, Elena T; Anderl, Janet L; Kirk, Christopher J; Zweegman, Sonja; Dijkmans, Ben Ac; Lems, Willem F; Scheper, Rik J; de Gruijl, Tanja D; Jansen, Gerrit

Verbrugge, Sue Ellen; Al, Marjon; Assaraf, Yehuda G; Niewerth, Denise; van Meerloo, Johan; Cloos, Jacqueline; van der Veer, Michael; Scheffer, George L; Peters, Godefridus J; Chan, Elena T; Anderl, Janet L; Kirk, Christopher J; Zweegman, Sonja; Dijkmans, Ben Ac; Lems, Willem F; Scheper, Rik J; de Gruijl, Tanja D; Jansen, Gerrit.

Afiliação

Verbrugge SE; Department of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands. g.jansen@vumc.nl.

Exp Hematol Oncol ; 2(1): 2, 2013 Jan 10.

Article em En | MEDLINE | ID: mdl-23305345

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Exp Hematol Oncol Ano de publicação: 2013 Tipo de documento: Article País de afiliação: Holanda

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google